The DREAM project (Dialogue for Reverse Engineering Assessments and Methods) is a veteran of big data challenges for neurodegenerative diseases. Back in 2012, DREAM partnered with Prize4Life to launch the DREAM-Phil Bowen ALS Prediction Prize4Life, with the goal to develop algorithms to predict disease progression in ALS patients based on large clinical datasets from the PRO-ACT database. This year, DREAM is partnering with Sage Bionetworks and the Global CEO Initiative on Alzheimer’s Disease (CEOi) to launch a big data challenge aiming to spur diagnostic innovation and to accelerate identification of Alzheimer’s disease biomarkers. The challenge solutions will be exciting to see – they are likely have applications for other neurodegenerative diseases too.
Click here to read more.Share this: